Boceprevir Meets Key Hep C Goals
Share
Follow Us
The Editors at Hepatitis Central
August 6, 2010
Late-stage studies show that boceprevir remains a Hepatitis C drug contender.
Merck says hepatitis C drug meets study goals
NEW YORK
Drug developer Merck & Co. said Wednesday its potential hepatitis C drug boceprevir met key goals in late-stage studies.
The company said the drug prompted immune system responses to fighting the disease in studies involving newly treated patients and patients taking additional treatments.
Continue reading this entire article:
http://www.businessweek.com/ap/financialnews/D9HCM6100.htm
